New heart failure drug passes first safety check in small study

NCT ID NCT05328752

Completed Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 24 times

Summary

This early-stage study tested a new drug called XXB750 in 27 adults with heart failure (a weakened heart). The main goal was to see if the drug is safe and what side effects it might cause. Participants received either the drug or a placebo, and researchers monitored their health closely. The study is now complete, and results will help decide if larger studies should move forward.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Fairview Health Services .

Saint Paul, Minnesota, 55102, United States
Jacksonville Ctr for Clin Rea Main Centre

Jacksonville, Florida, 32216, United States
Nature Coast Clinical Research LLC

Inverness, Florida, 34452, United States
Novartis Investigative Site

Groningen, 9713 GZ, Netherlands

Conditions

Explore the condition pages connected to this study.

HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF) OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF)